Personalis Inc.
Personalis is a company specializing in advanced genomic testing and liquid biopsy approaches for cancer detection, biomarker discovery, and clinical research. They focus on innovative sequencing technologies and comprehensive tumor profiling to support personalized medicine and cancer research.
Industries
Nr. of Employees
large (251-1000)
Personalis Inc.
Menlo Park, California, United States, North America
Products
Immunogenomic discovery platform (NGS-based)
A sequencing and computational platform that combines immunogenomic assays and neoantigen prediction to support biomarker discovery and immunotherapy research.
Immunogenomic discovery platform (NGS-based)
A sequencing and computational platform that combines immunogenomic assays and neoantigen prediction to support biomarker discovery and immunotherapy research.
Services
Liquid biopsy (ctDNA) testing service
Laboratory-based cfDNA extraction, targeted sequencing, and analytical reporting for ctDNA-based cancer detection and monitoring.
NGS-based tumor profiling service
Comprehensive tumor sequencing using augmented NGS to identify somatic variants, copy-number changes, and other genomic features for research or clinical use.
Neoantigen discovery and immunogenomics service
End-to-end neoantigen identification and prioritization from tumor and normal sequencing data to support immunotherapy development.
Biomarker discovery services
Assay and data workflows for discovery of genomic and immune biomarkers in solid and hematologic cancers, including custom study designs.
Analytical validation and assay qualification
Validation studies and performance qualification for NGS assays and discovery platforms, including reproducibility and accuracy assessments.
NGS support for clinical trials
Sequencing operations and data services structured to meet clinical trial workflows, including sample handling, sequencing, and result delivery.
Liquid biopsy (ctDNA) testing service
Laboratory-based cfDNA extraction, targeted sequencing, and analytical reporting for ctDNA-based cancer detection and monitoring.
NGS-based tumor profiling service
Comprehensive tumor sequencing using augmented NGS to identify somatic variants, copy-number changes, and other genomic features for research or clinical use.
Neoantigen discovery and immunogenomics service
End-to-end neoantigen identification and prioritization from tumor and normal sequencing data to support immunotherapy development.
Biomarker discovery services
Assay and data workflows for discovery of genomic and immune biomarkers in solid and hematologic cancers, including custom study designs.
Analytical validation and assay qualification
Validation studies and performance qualification for NGS assays and discovery platforms, including reproducibility and accuracy assessments.
NGS support for clinical trials
Sequencing operations and data services structured to meet clinical trial workflows, including sample handling, sequencing, and result delivery.
Expertise Areas
- Liquid biopsy and circulating tumor DNA analysis
- Tumor genomic profiling and characterization
- Neoantigen discovery and immunogenomics
- NGS assay design and validation
Key Technologies
- Next-generation sequencing (NGS)
- Cell-free DNA (cfDNA) / circulating tumor DNA (ctDNA) analysis
- Targeted oncology gene panels
- Neoantigen prediction algorithms